Simvastatin increases the activity of endothelial nitric oxide synthase via enhancing phosphorylation

Abstract

3-hydroxy-3-methylgulutaryl-coenzyme A (HMG-CoA) reductase inhibitors or statins are a kind of lipid-lowering agents and have been used for the prevention and treatment of cardiovascular diseases. Recent studies suggested that statins, besides lowering cholesterol, may protect vessels by enhancing the activity of endothelial nitric oxide synthase (eNOS). In the present study, we investigated if simvastatin increases eNOS activity through its phosphorylation in 293 cells (293-eNOS) with stable expression of eNOS. The results showed that incubation of 293-eNOS cells with simvastatin (10 μm/L) for 2 h significantly increased in the activity of eNOS as shown by the conversion of L-arginine to L-citrulline (2889.70±201.51 versus 5630.18±218.75 pmol/min · mg proteins) (P<0.01). Western blotting revealed that simvastatin increased phosphorylation of eNOS at 1177 (ser) and also 495 (thr) but did not affect the overall expression of eNOS or inducible NOS. Further study found that simvastatin raised phosphorylation levels of Akt and AMPK, and such effect could be antagonized by Akt inhibitor or AMPK inhibitor. These results suggest that simvastatin could stimulate the activity of eNOS via its phosphorylation by Akt and AMPK, which provides a new mechanism, other than lipid-lowering effect, for the cardiovascular protection of statins.

Keywords

simvastatin / nitric oxide synthase / phosphorylation / endothelial cells

References

[1] RandriamboavonjyV., FlemingI.. Endothelial nitric oxide synthase (eNOS) in platelets: how is it regulated and what is it doing there?. Pharmacol Rep, 2005, 57(Suppl59-65

[2] FeronO., BalligandJ.L.. Caveolins and the regulation of endothelial nitric oxide synthase in the heart. Cardiovasc Res, 2006, 69(4): 788-797

[3] ForstermannU., MunzelT.. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation, 2006, 113(13): 1708-1714

[4] YangZ., MingX.F.. Recent advances in understanding endothelial dysfunction in atherosclerosis. Clin Med Res, 2006, 4(1): 53-65

[5] UrbichC., DimmelerS.. Risk factors for coronary artery disease, circulating endothelial progenitor cells, and the role of HMG-CoA reductase inhibitors. Kidney Int, 2005, 67(5): 1672-1676

[6] WangH., LinL., JiangJ., et al. . Up-regulation of endothelial nitric-oxide synthase by endothelium-derived hyperpolarizing factor involves mitogen-activated protein kinase and protein kinase C signaling pathways. J Pharmacol Exp Ther, 2003, 307(2): 753-764

[7] MaronD.J., FazioS., LintonM.F.. Current perspective on statins. Circulation, 2000, 101(2): 207-213

[8] PaciaroniM., HennericiM., AgnelliG., et al. . Statins and stroke prevention. Cerebrovasc Dis, 2007, 24(2–3): 170-182

[9] YamadaT., NodeK., MineT., et al. . Long-term effect of atorvastatin on neurohumoral activation and cardiac function in patients with chronic heart failure: A prospective randomized controlled study. Am Heart J, 2007, 153(6): 1055.e1-8

[10] LaufsU., CustodisF., BöhmM.. HMG-CoA reductase inhibitors in chronic heart failure: potential mechanisms of benefit and risk. Drugs, 2006, 66(2): 145-154

[11] MartinJ.H., KrumH.. Statins and clinical outcomes in heart failure. Clin Sci (Lond), 2007, 113(3): 119-127

[12] LeferA.M., CampbellB., ShinY.K., et al. . Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation, 1999, 100(2): 178-184

[13] AbrahamS.S., OsorioJ.C., HommaS., et al. . Simvastatin preserves cardiac function in genetically determined cardiomyopathy. J Cardiovasc Pharmacol, 2004, 43(3): 454-461

[14] KureishiY., LuoZ., ShiojimaI., et al. . The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med, 2000, 6(8): 1004-1010

[15] Di NapoliP., TaccardiA.A., GrilliA., et al. . Chronic treatment with rosuvastatin modulates nitric oxide synthase expression and reduces ischemia-reperfusion injury in rat hearts. Cardiovasc Res, 2005, 66(3): 462-471

[16] CookeJ.P.. NO and angiogenesis. Atheroscler Suppl, 2003, 4(4): 53-60

[17] KalinowskiL., DobruckiL.W., BrovkovychV., et al. . Increased nitric oxide bioavailability in endothelial cells contributes to the pleiotropic effect of cerivastatin. Circulation, 2002, 105(8): 933-938

[18] LaufsU., LiaoJ.K.. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem, 1998, 273(37): 24 266-24 271

[19] RikitakeY., LiaoJ.K.. Rho GTPases, statins, and nitric oxide. Circ Res, 2005, 97(12): 1232-1235

[20] EssigM., NguyenG., PrieD., et al. . 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells: Role of geranylgeranylation and Rho proteins. Circ Res, 1998, 83(7): 683-690

[21] LaufsU., MarraD., NodeK., et al. . 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). J Biol Chem, 1999, 274(31): 21 926-21 931

[22] XiaY., DawsonV.L., DawsonT.M., et al. . Nitric oxide synthase generates superoxide and nitric oxide in arginine-depleted cells leading to peroxynitrite-mediated cellular injury. PNAS, 1996, 93(13): 6770-6774

[23] RamasamyS., ParthasarathybS., HarrisonD.G.. Regulation of endothelial nitric oxide synthase gene expression by oxidized linoleic acid. J Lipid Res, 1998, 89: 268-276

[24] BooY.C., SorescuG., BoydN., et al. . Shear stress stimulates phosphorylation of endothelial nitric-oxide synthase at ser1179 by akt-independent mechanisms. Role of protein kinase A. J Biol Chem, 2002, 277(5): 3388-3396

[25] HarrisM.B., JuH., VenemaV.J., et al. . Reciprocal phosphorylation and regulation of endothelial nitric-oxide synthase in response to bradykinin stimulation. J Biol Chem, 2001, 276(19): 16 587-16 591